|Bid||0.6100 x 0|
|Ask||0.6200 x 0|
|Day's Range||0.4850 - 0.6100|
|52 Week Range||0.0100 - 0.8900|
|Beta (5Y Monthly)||16.15|
|PE Ratio (TTM)||N/A|
|Earnings Date||Mar. 31, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
HALIFAX, Nova Scotia, June 29, 2020 -- MedMira Inc. (MedMira) (TSXV: MIR), reported today on its financial results for the quarter ended April 30, 2020. Important Notice The.
VANCOUVER , May 27, 2020 /CNW/ - Trading resumes in: Company: MedMira Inc. TSX-Venture Symbol: MIR (All Issues) Resumption (ET): 13:30 IIROC can make a decision to impose a temporary suspension (halt) ...
MedMira Inc. (MedMira) (MIR.V) announces that company has entered into an Exclusive Distribution Agreement with Webb Diagnostic Technologies, Inc., (WebbDX) for the distribution of MedMira’s REVEALCOVID-19™ Total Antibody Test. Webb Diagnostic Technologies has placed the first order with the purchase value of approximately CDN$3.5 million. The Company has received the down payment to initiate the production process.
VANCOUVER , May 27, 2020 /CNW/ - The following issues have been halted by IIROC: Company: MedMira Inc TSX-Venture Symbol: MIR (all issues) Reason: At the Request of the Company Pending News Halt Time (ET): 11:47 ...
Today, MedMira Inc. (MedMira) (MIR.V) announced that it has completed the registration process and affixed the CE mark (Conformité Européene) to its rapid REVEALCOVID-19™ Total Antibody Test. MedMira declares conformity to all essential requirements outlined in the In Vitro Diagnostic Medical Devices Directive 98/79/EC. The Certificate of Registration has been obtained from the European Authorized Representative and the product is now registered in the German DIMDI data base as per Directive 98/79/EC of the European Parliament and of the Council of the European Union relating to in vitro diagnostic medical devices.
MedMira Inc. (MedMira) (MIR.V), announced today that it had submitted the notification for the Emergency Use Authorization application offered by the U.S. Food and Drug Administration (FDA) for its newest member of its Reveal line of products for antibody testing. The FDA policy announced on March 16, 2020 permits MedMira to begin U.S. sales of REVEALCOVID-19TM total antibody test immediately while it awaits FDA clearance under Emergency Use Authorization (EUA).
MedMira Inc. (MedMira) (MIR.V), announced today that it has completed the development of the serological Point-of-Care (POC) testing solution with immediate result. Based on MedMira’s unique and patented Rapid Vertical Flow® (RVF) technology, the newly developed REVEALCOVID-19TM delivers immediate results without the need for any additional equipment such as a reader or a timer. The product is subject to obtaining regulatory approvals to sell in the selected markets.
MedMira Inc. (MedMira) (MIR.V), reported today on its financial results for the quarter ended January 31, 2020. Revenue: The Company recorded revenues in Q2 FY2020 of $95,012 compared to $129,990 in Q2 FY2019. The decrease of these revenues was due a change in ordering patterns by the Company’s main customer.
MedMira Inc. (MedMira) (MIR.V), reported today on its financial results for the quarter ended October 31, 2019. Revenue: The Company recorded revenues in Q1 FY2020 of $89,132 compared to $155,065 in Q1 FY2019. As outlined in the next highlight this strategy has provided the Company a higher contribution margin and also had an indirect effect on lowering its expenses.
Generally speaking long term investing is the way to go. But along the way some stocks are going to perform badly...
MedMira Inc. (MedMira) (MIR.V), reported today on its financial results for the financial year ended July 31, 2019. Revenue: The Company recorded revenues in FY2019 of $527,445 compared to $574,860 in FY2018. The decrease in revenue was due to the Company’s strategy to focus on high profit margin markets.